Eugeen Vanmechelen
Eugeen Vanmechelen
CSO, ADx NeuroSciences
Verified email at
Cited by
Cited by
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
K Blennow, A Wallin, H Ågren, C Spenger, J Siegfried, E Vanmechelen
Molecular and chemical neuropathology 26, 231-245, 1995
Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
F Hulstaert, K Blennow, A Ivanoiu, HC Schoonderwaldt, ...
Neurology 52 (8), 1555-1555, 1999
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
N Andreasen, L Minthon, P Davidsson, E Vanmechelen, H Vanderstichele, ...
Archives of neurology 58 (3), 373-379, 2001
Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease
N Andreasen, C Hesse, P Davidsson, L Minthon, A Wallin, B Winblad, ...
Archives of neurology 56 (6), 673-680, 1999
Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme‐linked immunosorbent assay
M Vandermeeren, M Mercken, E Vanmechelen, J Six, A Van de Voorde, ...
Journal of neurochemistry 61 (5), 1828-1834, 1993
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
M Goedert, R Jakes, E Vanmechelen
Neuroscience letters 189 (3), 167-170, 1995
Measurement of phosphorylated tau epitopes in the differential diagnosisof Alzheimer disease: a comparative cerebrospinal fluid study
H Hampel, K Buerger, R Zinkowski, SJ Teipel, A Goernitz, N Andreasen, ...
Archives of general psychiatry 61 (1), 95-102, 2004
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization
E Vanmechelen, H Vanderstichele, P Davidsson, E Van Kerschaver, ...
Neuroscience letters 285 (1), 49-52, 2000
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
C Hesse, L Rosengren, N Andreasen, P Davidsson, H Vanderstichele, ...
Neuroscience letters 297 (3), 187-190, 2001
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people
G De Meyer, F Shapiro, H Vanderstichele, E Vanmechelen, ...
Archives of neurology 67 (8), 949-956, 2010
Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values
M Sjogren, H Vanderstichele, H Ågren, O Zachrisson, M Edsbagge, ...
Clinical chemistry 47 (10), 1776-1781, 2001
Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology
A Olsson, H VANDERSticHELE, N Andreasen, G De Meyer, A WALLiN, ...
Clinical chemistry 51 (2), 336-345, 2005
A practical guide to immunoassay method validation
U Andreasson, A Perret-Liaudet, LJC van Waalwijk van Doorn, ...
Frontiers in neurology 6, 179, 2015
The β-secretase BACE1 in Alzheimer’s disease
H Hampel, R Vassar, B De Strooper, J Hardy, M Willem, N Singh, J Zhou, ...
Biological psychiatry 89 (8), 745-756, 2021
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
S Hall, A Öhrfelt, R Constantinescu, U Andreasson, Y Surova, F Bostrom, ...
Archives of neurology 69 (11), 1445-1452, 2012
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein
M Goedert, R Jakes, RA Crowther, P Cohen, E Vanmechelen, ...
Biochemical Journal 301 (3), 871-877, 1994
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
NJ Ashton, TA Pascoal, TK Karikari, AL Benedet, J Lantero-Rodriguez, ...
Acta neuropathologica 141, 709-724, 2021
Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma
H Vanderstichele, EV Kerschaver, C Hesse, P Davidsson, MA Buyse, ...
Amyloid 7 (4), 245-258, 2000
CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease
K Blennow, E Vanmechelen, H Hampel
Molecular neurobiology 24, 87-97, 2001
Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
O Hansson, H Zetterberg, E Vanmechelen, H Vanderstichele, ...
Neurobiology of aging 31 (3), 357-367, 2010
The system can't perform the operation now. Try again later.
Articles 1–20